To include your compound in the COVID-19 Resource Center, submit it here.

Pockets against pain

Amgen fills an allosteric pocket in GLRA3 to dampen neuropathic pain

Amgen Inc. (NASDAQ:AMGN) is aiming to tackle neuropathic pain by boosting glycine receptor α 3 (GLRA3) activity in the CNS. In a December study, the company presented preclinical data and crystal structures for its GLRA3 positive allosteric modulators (PAMs) that pointed to a new druggable pocket in the target.

Upon glycine binding, GLRA3

Read the full 525 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE